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AbstrAct:
The discovery of activating BRAF V600E mutations in 50% of all melanoma patients 
and the development of small molecule BRAF inhibitors looks set to revolutionize 
the therapy of disseminated melanoma. However, in the recent clinical trial of the 
BRAF inhibitor, vemurafenib (PLX4032), a significant percentage of BRAF V600E 
mutant melanoma patients did not meet the RECIST criteria for a response. Recent 
work from our lab identified loss of the tumor suppressor phosphatase and tensin 
homolog (PTEN) as being a possible mediator of intrinsic BRAF inhibitor resistance. 
In this commentary, we describe the development of a novel mass spectrometry 
based proteomic screen of Bcl-2 family proteins that was used to delineate the PTEN-
dependent differences in apoptosis signaling observed when BRAF was inhibited. 
We further discuss how use of these sensitive quantitative proteomic methods gives 
unique insights into the signaling of cancer cells that are not captured through 
routine biochemical techniques and how this may lead to the development of 
combination therapy strategies for overcoming intrinsic BRAF inhibitor resistance.
tArgeted therApy in melAnomA
Melanoma is the deadliest form of skin cancer. It 
arises from the malignant transformation of melanocytes 
and has long been notorious for its resistance to 
chemotherapy, radiotherapy and immunotherapy. 
In recent years, great strides have been made in our 
understanding of the underlying genetic and biological 
basis of melanoma initiation and development. We now 
stand at an exciting juncture in melanoma research in 
which our accumulated knowledge about melanoma 
biology is translating into new therapeutic strategies. One 
key discovery of the last decade is the identification of 
activating mutations in the serine/threonine kinase BRAF 
in up to 50% of all melanomas [1]. There is now good 
evidence that mutated BRAF is a key initiating event 
in melanoma development and that continuous BRAF 
signaling is required for melanoma progression [2, 3]. 
Most of the transforming activity of mutant BRAF is 
mediated through the activation of the RAF/MEK/ERK 
signaling pathway which drives cell cycle dysregulation 
and uncontrolled growth by reducing expression of the 
cyclin dependent kinase inhibitor p27 and by increasing 
the expression of cyclin D1 [4, 5]. In addition to its effects 
upon cell growth, mutant BRAF also contributes to the 
oncogenic phenotype of melanoma cells through both 
down regulation of apoptotic signals and enhancement 
of cell invasion  [6-9]. Recent clinical studies have 
demonstrated that the presence of a BRAF mutation is 
prognostic for melanoma and is associated with reduced 
survival in the metastatic setting [10]. 
The discovery of activating BRAF mutations in 
melanoma prompted a flurry of drug discovery activity 
and the development of small molecule BRAF inhibitors. 
The list of BRAF inhibitors currently undergoing 
preclinical and clinical evaluation includes XL281, 
SB590885, GDC-0879, GSK2118438, AZ628 and 
PLX4032 [11-14]. Of these, PLX4032 (vemurafenib) and 
its analog, PLX4720, have been most extensively studied 
[13, 15-18]. Treatment of melanoma cell lines and mouse Oncotarget 2011; 2:  329 - 335 330 www.impactjournals.com/oncotarget
xenografts with PLX4032/4720 led to both G1 phase cell 
cycle arrest and the induction of apoptosis [13, 15]. The 
effects of PLX4032 were noted to be BRAF mutation 
specific, and equivalent responses were seen in melanoma 
models with both heterozygous and homozygous BRAF 
mutations [13]. No anti-proliferative or cytotoxic effects 
were observed in melanoma cell cultures that lacked 
the BRAF mutation. Interestingly, not all BRAF mutated 
melanoma cell lines were similarly sensitive to PLX4032 
and PLX4720 though, with some cell lines exhibiting 
intrinsic resistance [17-19]. 
In the phase I clinical trial, vemurafenib led to 
significant levels of tumor shrinkage in 80% of patients 
whose melanomas harbored the BRAF V600E mutation 
[20]. This was an unprecedented result for a melanoma 
clinical trial and quickly led to the initiation of both 
phase II and phase III single agent trials [21]. The phase 
III trial of vemurafenib closed early when the primary 
progression free survival endpoint was met and the data 
has been submitted to the FDA for regulatory approval. 
Although the results from the vemurafenib trial were 
very impressive, responses were unfortunately short-
lived with most patients ultimately failing therapy and 
becoming resistant (median progression free survival ~7 
months) [20]. The development of strategies to manage 
and overcome acquired BRAF inhibitor resistance is 
now the major challenge facing the melanoma research 
community. 
The emerging evidence suggests that acquired 
resistance to vemurafenib is complex and multi-factorial 
[17, 22-26]. Already, studies have shown that resistance 
can be mediated via increased receptor tyrosine kinase 
(RTK) signaling, the acquisition of activating mutations 
in NRAS, novel mutations in MEK1 and up regulation 
of MAP3K8 (Cot) [22-26]. Although the resistance 
mechanisms reported thus far are diverse, most are 
associated with the re-establishment of MAPK signaling 
and/or an increase in PI3K/AKT/mTOR signaling [22-
26]. Clinical trials are currently ongoing to validate the 
combination of BRAF and MEK inhibitors in BRAF 
V600E mutant melanoma, with trials on the combination 
of BRAF with AKT inhibitors due to commence in the 
near future. The end goal of these studies is to define 
an optimal combination therapy strategy with the aim 
of extending the time to relapse and improving overall 
survival.
Using proteomics to UnderstAnd 
the mechAnisms of intrinsic brAf 
inhibitor resistAnce
Approximately 20% of BRAF V600E mutant 
melanoma patients on the phase I trial of vemurafenib 
appeared to be intrinsically resistant and did not meet the 
RECIST criteria for a response [20]. Although uniquely 
addicted to MAPK signaling, melanomas are also known 
to require signaling activity in many other pathways, 
with the PI3K/AKT pathway thought to be particularly 
important for both melanoma initiation and progression 
[2, 27, 28]. In a recent study, our lab identified loss of 
expression of the tumor suppressor phosphatase and 
tensin homolog (PTEN) as being predictive for an 
impaired apoptotic response when BRAF was inhibited 
[29]. Mechanistically it was noted that inhibition of 
BRAF in PTEN null melanoma cells was associated with 
an increase in phospho-AKT expression which led in turn 
to the decreased nuclear accumulation of FOXO3a [29]. 
As no studies had yet addressed the mechanism by 
which PTEN expression regulated the apoptotic response 
following BRAF inhibition, we developed a novel mass 
spectrometry based technique to simultaneously quantify 
a large panel of Bcl-2 family proteins. As our approach, 
we used selected reaction monitoring mass spectrometry 
(SRM-MS), a method that was originally developed to 
enable  quantification  of  analytes  in  complex  mixtures. 
This technology (LC-SRM-MS) has been applied to the 
detection and quantification of small molecules (MW < 
500 Da) for decades, and is used routinely to test for drugs 
of  abuse  and  performance  enhancement  and  to  define 
pharmacokinetics and pharmacodynamics of therapeutic 
compounds. It was first applied to endogenous peptides 
in the early 1990’s [30]. However, the use of triple 
quadrupole mass spectrometers to monitor proteolytic 
peptides as surrogates for the expression of a protein 
was  first  described  in  1996  [31].  LC-MRM  with  the 
addition of spiked stable isotope labeled peptides enables 
quantification of the number of moles (or molecules) of 
the endogenous protein; this method has been termed 
absolute quantification (AQUA) [32-34]. It is important 
to note that this technique establishes a minimum value 
for the amount of the protein as the digestion and peptide 
recovery are incomplete (although they are extremely 
consistent). 
When analyzing multiple fragments from different 
molecules, the technique is also called multiple reaction 
monitoring mass spectrometry (MRM-MS). The 
“reaction” is the conversion of the intact molecule into 
fragment ion(s) specific for its structure (see Figure 1A); 
this molecule-fragment pair is also termed a transition. 
Each “reaction” is optimized by the choice of background 
gas (typically argon or nitrogen) the pressure in the 
collision cell, and the collision energy applied. When 
coupled with reversed-phase liquid chromatography, three 
characteristics of the molecule are used to isolate its signal 
for detection and quantification: hydrophobicity (which 
defines the elution time), the mass-to-charge ratio (m/z) 
of the intact molecule, and fragment ion mass-to-charge 
ratio. 
This research arena is extremely active and 
competitive; methods for assessment of panels of protein 
biomarkers and pipeline development have been described 
in recent publications [35-39]. Furthermore, LC-MRM Oncotarget 2011; 2:  329 - 335 331 www.impactjournals.com/oncotarget
shows promise in translation to the assessment of patients. 
Of equal importance, LC-MRM can be effective in 
elucidating biological processes; this technology has been 
used to monitor protein post-translational modifications as 
well as signaling networks [40-42]. Our study used SDS-
PAGE protein fractionation combined with LC-MRM 
detection  and  quantification  to  evaluate  the  expression 
of apoptosis-regulating proteins in the Bcl-2 family. The 
quantification of multiple family members is critical due 
to the redundancy of their function, and LC-MRM has the 
capability to measure large numbers of low abundance 
proteins in a single experiment. Quantification of these 
proteins revealed a differential up regulation of BIM 
between the PTEN expressing and PTEN null cells when 
BRAF was inhibited (14-fold increase vs 4-fold increase, 
respectively) (Figure 1B) [29]. 
 BIM is a pro-apoptotic BH3-only domain protein 
that is regulated both transcriptionally and post-
transcriptionally by many signaling pathways including 
BRAF/MEK/ERK, PI3K/AKT, p38 MAPK and JNK/
SAPK [43]. It exerts its pro-apoptotic effects by binding to 
and antagonizing the anti-apoptotic proteins Bcl-2, Bcl-w, 
Bcl-XL and Mcl-1 [44, 45]. In BRAF mutant melanoma 
cells, inhibition of BRAF using small molecule inhibitors 
and siRNA knockdown leads to the induction of apoptosis 
via a mechanism involving the decreased phosphorylation 
of BAD at Ser-75, an upregulation of BMF and an increase 
in BIM expression [6, 46, 47]. The identification of BIM as 
a key PTEN-regulated apoptotic mediator in BRAF mutant 
melanoma cells allowed a novel mechanism of intrinsic 
drug resistance to be elucidated whereby the paradoxical 
activation of AKT in PTEN null cells led to a suppression 
figure 1: liquid chromatography multiple reaction monitoring mass spectrometry: principle and practice. After 
reversed-phase HPLC separation, peptides are selected by their mass-to-charge ratio and dissociated by collisions with background gas before 
the fragment ions are mass selected to enable specific detection and quantification of individual peptides in complex mixtures (A).  This 
technique was applied to the measurement of expression of apoptosis-regulating proteins in the Bcl-2 family to determine the mechanism for 
PTEN null melanoma cells’ resistance to the BRAF V600E inhibitor, PLX4720 (inset).  Both the heat map and the bar graph indicate that the 
major difference between the two cell lines was the upregulation of Bim, which caused apoptosis in PTEN positive cells.  Regulation of the 
other Bcl-2 family proteins was similar regardless of PTEN status.
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of the nuclear accumulation of FOXO3a and a reduction 
in BIM mRNA [29]. Of potential clinical relevance it 
was noted that dual inhibition of both BRAF and PI3K 
restored nuclear FOXO3a accumulation, upregulated 
BIM expression at the mRNA and protein levels and 
enhanced the level of apoptosis [29]. Similar results were 
also noted in melanoma cells intrinsically resistant to 
the MEK inhibitor AZD6244, where sensitivity could be 
restored by the dual inhibition of both MEK and IGF1R, 
mTORC1/2 or AKT [48]. Further support for the role for 
AKT signaling in intrinsic BRAF inhibitor resistance 
came from other studies showing that overexpression of 
an active form of AKT3 (myristolated AKT3) prevented 
apoptosis in BRAF V600E mutant melanoma cells when 
BRAF was inhibited [49].
The use of LC-MRM allowed the level of BIM 
expression  to  be  identified  as  a  PTEN-dependent 
determinant of BRAF inhibitor mediated apoptosis. If 
it were not for the exquisite sensitivity of the LC-MRM 
approach and the ability to accurately quantify peptide 
levels, the PTEN dependency of BIM expression in this 
process may not have been realized. The utility and value of 
LC-MRM comes primarily from the fact that experiments 
can be designed to evaluate the full complexity and detail 
of biological processes in different human disease states. 
cUrrent vAlUe And projected 
fUtUre potentiAl of lc-mrm 
protein qUAntificAtion
Quantitative  mass  spectrometry,  particularly  LC-
MRM, is emerging as an alternative to antibody-based 
methods for the detection and quantification of proteins 
(such as Western Blotting). The development of peptide-
based  assays  for  protein  expression,  modification,  and 
even mutations can be implemented very rapidly [50]. 
The selection of the target peptide sequence from either 
existing tandem mass spectrometry data or LC-MRM 
screening of peptide candidates, synthesis of stable 
isotope-labeled standards, and analysis to examine the 
match between the elution time and fragmentation patterns 
of the endogenous and standard peptide can be completed 
within a few days. Current mass spectrometers can 
analyze hundreds to thousands of transitions (peptide and 
fragment pairs) in each experiment enabling quantification 
of numerous proteins. While one peptide could be used 
as a surrogate, typically three or more transitions from 
three or more peptides are recommended for quantifying 
protein expression. Unlike antibody-based methods that 
are completely reliant on the reagents and the epitopes 
that they recognize, protein measurements with LC-MRM 
have a great deal more flexibility [51]. If an assay has 
interference, additional steps can be taken to change the 
protein purification, select another peptide, or even just 
select a different fragment ion from the same peptide. 
Through its versatility and capacity for multiplexing, LC-
MRM platforms should soon emerge as competitors for 
array technologies. Just as peptide sequencing with liquid 
chromatography-tandem mass spectrometry (LC-MS/
MS) has revolutionized biology, the ability of LC-MRM 
to detect and quantify low abundance targets determined a 
priori represents the next potential impact that proteomics 
can have on the study of human disease. As we have 
demonstrated, these methods have particular utility 
in unraveling how the genetic makeup of cancer cells 
can dictate drug response. As cancer therapy becomes 
ever more personalized, and the LC-MRM technology 
becomes more sophisticated, a future can be envisioned 
in which the key determinants of drug response can be 
determined in individual patient samples. It is hoped 
that these new approaches could allow therapies to be 
specifically tailored to individual patients so that efficacy 
can be maximized and off-target effects minimized.
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